Sangamo Announces Agreement Securing Access To Large-Scale, Commercial-Grade Manufacturing Capacity At Brammer Bio

BRISBANE, Calif., April 2, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has signed an option agreement with Brammer Bio, a gene therapy contract development and manufacturing organization, to secure access to large-scale...

from PR Newswire: https://ift.tt/2OCHLzJ